307 related articles for article (PubMed ID: 34144111)
1. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
2. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
3. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Dwyer DF; Ordovas-Montanes J; Katz HR; Lewis E; Vukovic M; Lai J; Bankova LG; Bhattacharyya N; Shalek AK; Barrett NA; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2020 Jun; 145(6):1574-1584. PubMed ID: 32199912
[TBL] [Abstract][Full Text] [Related]
4. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
5. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Buchheit KM; Sohail A; Hacker J; Maurer R; Gakpo D; Bensko JC; Taliaferro F; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
[TBL] [Abstract][Full Text] [Related]
6. Steroids Inhibit Eosinophil Accumulation and Downregulate Hematopoietic Chemotaxic Prostaglandin D
Suzuki N; Ko-Mitamura EP; Inui T; Terada T; Dejima K; Nagata N; Urade Y; Kawata R
Ear Nose Throat J; 2021 Sep; 100(5_suppl):738S-745S. PubMed ID: 32077309
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
Cahill KN; Bensko JC; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2015 Jan; 135(1):245-52. PubMed ID: 25218285
[TBL] [Abstract][Full Text] [Related]
9. Levels of eicosanoids in nasal secretions associated with nasal polyp severity in chronic rhinosinusitis.
Nordström A; Jangard M; Svedberg M; Ryott M; Kumlin M
Prostaglandins Leukot Essent Fatty Acids; 2022 Sep; 184():102474. PubMed ID: 35917595
[TBL] [Abstract][Full Text] [Related]
10. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
11. Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease.
Sohail A; Hacker J; Ryan T; McGill A; Bergmark R; Bhattacharyya N; Lee SE; Maxfield A; Roditi R; Julé AM; Griffith A; Lederer J; Laidlaw TM; Buchheit KM
J Allergy Clin Immunol; 2024 Feb; 153(2):527-532. PubMed ID: 37898408
[TBL] [Abstract][Full Text] [Related]
12. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim MA; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):1-6. PubMed ID: 24300420
[TBL] [Abstract][Full Text] [Related]
13. A trial of type 12 purinergic (P2Y
Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
[TBL] [Abstract][Full Text] [Related]
14. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Luskin K; Thakrar H; White A
Immunol Allergy Clin North Am; 2020 May; 40(2):329-343. PubMed ID: 32278455
[TBL] [Abstract][Full Text] [Related]
15. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
16. Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.
Jerschow E; Edin ML; Chi Y; Hurst B; Abuzeid WM; Akbar NA; Gibber M; Fried MP; Han W; Pelletier T; Ren Z; Keskin T; Roizen G; Lih FB; Gruzdev A; Bradbury JA; Schuster V; Spivack S; Rosenstreich D; Zeldin DC
J Allergy Clin Immunol Pract; 2019; 7(5):1580-1588. PubMed ID: 30580047
[TBL] [Abstract][Full Text] [Related]
17. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Wangberg H; Spierling Bagsic SR; Osuna L; White AA
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):478-484.e3. PubMed ID: 34597850
[TBL] [Abstract][Full Text] [Related]
18. Eosinophil production of prostaglandin D
Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Priyadharshini VS; Jiménez-Chobillon MA; de Graaf J; Porras Gutiérrez de Velasco R; Gratziou C; Ramírez-Jiménez F; Teran LM
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439758
[TBL] [Abstract][Full Text] [Related]
20. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
